Mivalsecovatein
As of the edition of 20 October 2026, Mivalsecovatein is a protein: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Brand name
- Nuvaxovid Xbb.1.5
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Sanofi
- Registered trials
- 2, 0 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novavax | Lead sponsor of trials | 2023 to now |